CASI Pharmaceuticals, Inc. (CASI) Stock

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.

CASI Pharmaceuticals, Inc. is headquartered in CN.

CASI Pharmaceuticals, Inc. (CASI) stock trades at $0.15 with a market capitalization of $2.33M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.07, reflecting a net loss over the last twelve months, a negative price-to-book of -0.08, reflecting negative shareholders' equity, price-to-sales of 0.17. Over the past 52 weeks the stock has ranged between $0.14 and $3.09, and currently trades 95.1% below its 52-week high.

On profitability, CASI Pharmaceuticals, Inc. generates a return on equity (ROE) of 184.34% (not meaningful, as shareholders' equity is negative), return on capital employed of 215.13%, an operating margin of -238.55%, a net profit margin of -259.51%.

Official website: www.casipharmaceuticals.com

CASI Pharmaceuticals, Inc. by the numbers, 2015–2024

Between 2015 and 2024 CASI Pharmaceuticals, Inc. reported revenue of $0 rising to $29.0M. Compounded, revenue has grown 48.6% a year over five years, -1.1% over three, -14.7% over the last twelve months. Net profit fell to $-39.0M.

Operating margin went from 14990.8% in 2015 to -138.8% in 2024, a fall of 15129.6 percentage points. The most recent net margin is -259.51%. On a trailing twelve-month basis to Sep '25, revenue is $26.0M and net profit $-49.0M.

Borrowings rose from $1.0M to $22.0M, cash on hand is $4.7M, cash from operations was $-29.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -451.1% over five years, and was -1950.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

CASI Pharmaceuticals, Inc. (CASI) — frequently asked questions